Who we represent
The high-tech world continues to create opportunities for technological entrepreneurial innovation in the field of healthcare and life sciences. Alongside these opportunities, there exist significant and complex legal challenges.
Our firm’s healthcare and life sciences department advise a broad range of life science companies, including, pharmaceutical companies, medical device companies, digital health companies, technological incubators, start-up and scale-up companies and research institutions. Our firm also advises investors and strategic players in this field, including angel investors, dedicated local and international VC funds, and global big pharma. Our practice covers pharmaceuticals, biopharma, e-health, med-tech and medical cannabis.
What we do
Transactions
- We advise companies through all stages of their capital raising, in complex local and international investment transactions, as well as for mergers and acquisitions.
- We work with clients throughout their entire lifecycle: from the early days of formation including advising on business strategy, capital raising, preparing and negotiating commercial agreements, to access to local and international governmental grants and regulatory reporting.
- We have one of the leading practices working with investors and start-ups to win support and funding from the Israeli government through the Israeli Innovation Authority. Past successful tenders on which we have advised include med tech and healthcare programmes.
Recent experience includes:
- Acting for one of Israel’s unicorns, a medical imaging company, on its US$190 million IPO on Nasdaq and subsequent acquisition of a medical imaging analytics company.
- Representing a med-tech company on a multimillion-dollar commercial agreement to deploy its imaging system in Africa.
- Advising one of Israel’s leading venture capital teams on its investment in a company developing an AI-backed medical diagnostic system.
- Representing an Israeli-US investment fund focusing on digital healthcare on fund formation and investments in start-ups.
- Handling the formation of aMoon Growth II fund, which is targeting the raising of USD750 million
Intellectual property
- Our department advises on the commercialisation of technologies developed at academic institutions and public medical institutions including production agreements and joint development agreements.
- We also advise on the licensing processes for medical devices, as well as on research and development that is subject to Israeli regulation.
Recent experience includes:
- Representing a global manufacturer of innovative medical aesthetics products on intellectual property issues including trademarks and confidentiality.
Regulation
- Our department has special expertise in privacy, information security and regulation and their application to medical databases.
- We advise on healthcare data and global compliance including the application of the EU’s General Data Protection Regulation (GDPR); compliance with clinical trial regulation; and on US regulations including the Health Insurance Portability and Accountability Act (HIPAA).
Recent experience includes:
- Advising a global clinical-stage biopharmaceutical company on its compliance with the EU’s GDPR and the US federal Health Insurance and Portability Act in relation to data aspects of clinical trial activity as well as trial regulations.
- Providing a comprehensive overview for a laser-therapy technology client on its compliance with GDPR and HIPAA regulation and global data protection requirements.
Why choose us?
We offer a one-stop shop for healthcare and life sciences advice: we combine expertise in transactions, capital raising and intellectual property protection with a global regulatory practice. It means we offer consistent and trusted support as you expand into new markets and products.
Our team is recognised as a leading firm by independent research: we are ranked among the top firms for Healthcare and Life Sciences by The Legal 500.
“Recent highlights also saw the team assisting hi-tech and start-up companies with the commercialisation of their IP and representing them before the Israeli Innovation Authority”.
The Legal 500 (2022).
For further information or to discuss your business in confidence, please reach out to our partners below.
